{"schema_version":"secwatch.filing_event.v1","accession":"0001701478-25-000041","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.707237+00:00","generated_at":"2026-05-17T15:32:45.418448+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Azitra Q2 net loss $2.9M; cash $1.0M; ATR-12 Phase 1b shows safety","bullets":["Net loss of $2.9M for Q2 2025, up from $2.6M in Q2 2024; R&D spend $1.4M, G&A $1.5M.","Cash and equivalents $1.0M as of June 30, 2025; entered $20M equity line with Alumni Capital LP.","ATR-12 Phase 1b in Netherton syndrome: 50% enrolled, promising safety in first 5 patients.","ATR-04 Phase 1/2 for EGFRi rash: design presented at ASCO; first patient dosing expected Q3 2025.","Anticipated topline data for ATR-12 in Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001701478-25-000041","json":"https://secwatch.observer/filing/0001701478-25-000041.json","markdown":"https://secwatch.observer/filing/0001701478-25-000041.md","text":"https://secwatch.observer/filing/0001701478-25-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000170147825000041/0001701478-25-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000170147825000041/aztr-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:32:45.418448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}